ניופוגן 30 mu בקבוקונים
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
ניופוגן mu 48 מזרק מוכן לשימוש
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
ניופוגן mu 30 מזרק מוכן לשימוש
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
קלוטרי
teva pharmaceutical industries ltd, israel - clotrimazole - טבליות וגינליות - clotrimazole 200 mg - clotrimazole - clotrimazole - vaginal fungal infections caused mainly by candida species. vaginal infections caused by trichomonas and microorganisms sensitive to clotrimazole.
קלוטרי
teva pharmaceutical industries ltd, israel - clotrimazole - טבליות וגינליות - clotrimazole 200 mg - clotrimazole - clotrimazole - vaginal fungal infections caused mainly by candida species. vaginal infections caused by trichomonas and microorganisms sensitive to clotrimazole.
קלוטרי
teva israel ltd - clotrimazole - טבליות וגינליות - clotrimazole 200 mg - clotrimazole
פיוריטי-פיור&קליר-פילינג תלת אקטיבי
נאוטק קבוצת קורדן בעמ - שיפור מראה העור